hims bpc 157 jumps more than 7% after an FDA panel recommends adding BPC-157 to the 503A compounding list potentially opening a new peptide category. The opportunity fits Hims existing telehealth, compounding and customer HIMS 🚨 THE VOTE FOR

3T3-L1 cells were cultured in 60 mm diameter dishes (8.4104 cells/dish) and treated with NNMT inhibitor dissolved in culture media with/without adipogenic factors (1 mM IBMX, 1 M dexamethasone, 10 g/ml of insulin) during each of the scheduled media changes during the differentiation process (described above)

The sample is then sent to a state-certified laboratory for precise analysis

It was discovered more than 30 years ago, and in all that time, not one controlled human trial of it has been published

The use of Semaglutide / Cyanocobalamin Injection is contraindicated in several specific patient populations and clinical situations where the risks associated with treatment may outweigh potential benefits